Nutrigene Biosciences Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 27-10-2024
- Paid Up Capital ₹ 4.66 Cr
as on 27-10-2024
- Company Age 4 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 22016.85%
(FY 2023)
- Profit -424.58%
(FY 2023)
- Ebitda -434.00%
(FY 2023)
- Net Worth -42.52%
(FY 2023)
- Total Assets 7.40%
(FY 2023)
About Nutrigene Biosciences
The Corporate was formerly known as Ikigai Bioworks Private Limited. The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 4.66 Cr, as per Ministry of Corporate Affairs (MCA) records.
Tejash Shah, Raheel Shah, Trushit Mehta, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24290TG2020PTC145055
- Company No.
145055
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Oct 2020
- Date of AGM
09 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Nutrigene Biosciences?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Tejash Shah  | Director | Current | |
| Raheel Shah | Director | Current | |
| Trushit Mehta | Director | Current | |
| Katta Kumar | Director | Current | |
| Keerthi Vadlamani | Director | 20-Oct-2020 | Current |
Financial Performance of Nutrigene Biosciences.
Nutrigene Biosciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 22016.85% increase. The company also saw a substantial fall in profitability, with a 424.58% decrease in profit. The company's net worth observed a substantial decline by a decrease of 42.52%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nutrigene Biosciences?
In 2023, Nutrigene Biosciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Spinos Life Science And Research Private LimitedActive 8 years 8 monthsRaheel Shah is a mutual person
Bdr Lifesciences Private LimitedActive 31 years 2 monthsTejash Shah, Raheel Shah and 1 more are mutual person
- Bdr Pharmaceuticals International Private LimitedActive 22 years 2 months
Tejash Shah and Raheel Shah are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Nutrigene Biosciences?
Nutrigene Biosciences has a workforce of 0 employees as of Mar 27, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nutrigene Biosciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nutrigene Biosciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
